Drug interactions
Bendamustine + Ciltacabtagene autoleucel
Severity: Major
Bendamustine and Ciltacabtagene autoleucel: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Bendamustine is lymphotoxic and myelosuppressive. Recent exposure before apheresis can reduce T-cell yield and quality, and use after infusion may harm CAR T cells and raise infection risk.
What this interaction means in plain words
Bendamustine and Ciltacabtagene autoleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Bendamustine belongs to Oncology; Ciltacabtagene autoleucel belongs to Miscellaneous.
Why it happens
Additive immunosuppression and lymphodepletion with potential cytotoxicity to T cells.
What to do
Observe the recommended washout interval between bendamustine and apheresis, and avoid it after infusion except in a planned lymphodepletion protocol. Monitor blood counts and infections.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Bendamustine and Ciltacabtagene autoleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Bendamustine
Other interactions of Ciltacabtagene autoleucel
Frequently asked questions
Can I take Bendamustine with Ciltacabtagene autoleucel?
MediHelp rates the interaction as major. Bendamustine and Ciltacabtagene autoleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Bendamustine is lymphotoxic and myelosuppressive. Recent exposure before apheresis can reduce T-cell yield and quality, and use after infusion may harm CAR T cells and raise infection risk.
How serious is the interaction between Bendamustine and Ciltacabtagene autoleucel?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Observe the recommended washout interval between bendamustine and apheresis, and avoid it after infusion except in a planned lymphodepletion protocol. Monitor blood counts and infections.
What other medicines interact with Bendamustine?
MediHelp also lists interactions of Bendamustine with, for example, Axicabtagene ciloleucel, Brexucabtagene autoleucel, Chlorambucil. The full list is on the Bendamustine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
